Ally Bridge backs Chinese oncology-focused big data company

Financial details of the investment were not disclosed. According to a release, participants in the round included both Chinese and international GPs. Ally Bridge plans to facilitate collaboration between LinkDoc and its other portfolio companies in the US, Europe and China to enhance LinkDoc's leadership role in China's healthcare big data space.

LinkDoc partners with more than 200 oncology hospitals in China to create a database of medical records and clinical data, which it uses to assist doctors through an analytics platform. The company is working to make its database available to pharmaceutical companies to help with drug development and marketing.

"Big data-driven personalized medicine has become an irreversible trend in global healthcare," said Frank Yu, founder and CEO of Ally Bridge. "The investment in LinkDoc highlights Ally Bridge's further commitment to investing in precision medicine and healthcare IT on a global basis, especially in the U.S. and China."

Founded in 2010 as Themes Investment Partners, Ally Bridge pursues a cross-border strategy, seeking healthcare-focused investments in both the US and China. In China, the firm led the privatization of WuXi PharmaTech last year, along with the firm's management. Its US investments include San Diego-based molecular diagnostics company AltheaDX.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Save this article  
• Send to  

• Topics
• Greater China
• Healthcare
• Technology
• Expansion
• China
• Ally Bridge
• Growth capital